drugset
drugset / Trial / NCT00394446

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

NCT00394446 ↗

Phase 1 Completed 48 enrolled Myrexis Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.

Timeline

Start
2005-03
Primary completion
2007-04
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Verubulin Small molecule — Intravenous

Indications

refractory malignant neoplasm